Navidea Biopharmaceuticals, Inc. (NAVBQ) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Navidea Biopharmaceuticals, Inc. (NAVBQ) trades at $0.0001 with AI Score 43/100 (Grade C). Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing precision immunodiagnostic agents and immunotherapeutics. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for NAVBQ: NAVBQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NAVBQ against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
NAVBQ: 1/3 scored disciplines lean bearish. Dominant signal: Ken Griffin bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Navidea Biopharmaceuticals, Inc. (NAVBQ) Healthcare & Pipeline Overview
Navidea Biopharmaceuticals, Inc., operating in the biotechnology sector, focuses on precision immunodiagnostic agents and immunotherapeutics. Their Manocept platform targets the CD206 mannose receptor for diagnostic modalities and therapeutic delivery. Currently under Chapter 11 reorganization, the company faces significant financial and operational challenges within a competitive landscape.
What Is the Investment Thesis for NAVBQ?
Navidea Biopharmaceuticals, Inc. faces significant challenges given its Chapter 11 reorganization filing in October 2025. The company's negative profit margin of -23117.6% and gross margin of -259.4% highlight severe financial difficulties. While the Manocept platform and pipeline of immunodiagnostic agents and immunotherapeutics represent potential value, the company's ability to navigate bankruptcy proceedings and secure funding for continued development is uncertain. Upcoming clinical trial results for NAV3-33 (Phase III) and NAV3-32 (Phase 2b) in RA could serve as catalysts, but the high beta of -5.96 indicates extreme volatility. Investors should carefully consider the high-risk nature of this investment.
Based on FMP financials and quantitative analysis
NAVBQ Key Highlights
Market capitalization of $0.00B reflects the company's distressed financial state and Chapter 11 filing.
- Profit margin of -23117.6% indicates substantial losses and operational inefficiencies.
- Gross margin of -259.4% demonstrates that the cost of goods sold significantly exceeds revenue.
- Beta of -5.96 suggests the stock price moves inversely and with greater magnitude compared to the market, indicating high volatility.
- The company filed for Chapter 11 reorganization on October 1, 2025, introducing significant uncertainty about its future.
Who Are NAVBQ's Competitors?
NAVBQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NAVBQ's Key Strengths?
Proprietary Manocept platform.
- Pipeline of clinical-stage immunodiagnostic agents.
- Expertise in targeting the CD206 mannose receptor.
- Potential for expansion into immunotherapeutics.
What Are NAVBQ's Weaknesses?
Chapter 11 reorganization.
- Negative profit and gross margins.
- Limited financial resources.
- Dependence on clinical trial success.
What Could Drive NAVBQ Stock Higher?
Potential outcomes from Chapter 11 reorganization proceedings could significantly impact the company's future.
- Clinical trial results for NAV3-33 (Phase III) in rheumatoid arthritis could drive investor interest.
- Development of Tc99m tilmanocept for cardiovascular applications may open new markets.
- Strategic partnerships and licensing agreements could provide financial support and expertise.
- Advancements in immunotherapeutics market may create new opportunities for the Manocept platform.
What Are the Key Risks for NAVBQ?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Chapter 11 reorganization introduces significant uncertainty and risk of liquidation.
- Competition from larger biotechnology companies with greater resources.
- Regulatory hurdles and clinical trial failures could delay or halt product development.
- Inability to secure funding could jeopardize the company's operations.
- Limited liquidity and wide bid-ask spreads in the OTC market.
What Are the Growth Opportunities for NAVBQ?
- Expansion of Manocept Platform Applications: The Manocept platform's ability to target the CD206 mannose receptor offers opportunities to expand its applications across various diagnostic modalities, including SPECT, PET, and optical-fluorescence detection. The market for molecular imaging is projected to reach $8.2 billion by 2027, driven by advancements in imaging technologies and increasing demand for early disease detection. Successful development and commercialization of new Manocept-based diagnostic agents could drive revenue growth for Navidea, provided it can secure necessary funding and regulatory approvals.
- Advancement of RA Pipeline: Navidea's pipeline includes NAV3-31, NAV3-35, NAV3-33, and NAV3-32, all targeting rheumatoid arthritis (RA) imaging. The global RA therapeutics market is expected to reach $32.4 billion by 2028, driven by an aging population and increasing prevalence of autoimmune diseases. Positive clinical trial results and subsequent regulatory approvals for these candidates could provide significant revenue streams for Navidea. However, the company's financial constraints and Chapter 11 filing pose challenges to advancing these programs.
- Development of Tc99m Tilmanocept for Cardiovascular Applications: Navidea is exploring the use of Tc99m tilmanocept for cardiovascular applications. Cardiovascular diseases remain a leading cause of death worldwide, creating a substantial market for diagnostic and therapeutic interventions. Successful development and commercialization of Tc99m tilmanocept for cardiovascular imaging could open new revenue opportunities for Navidea, contingent on securing funding and navigating regulatory pathways.
- Strategic Partnerships and Licensing Agreements: Navidea could pursue strategic partnerships and licensing agreements to leverage its Manocept platform and pipeline assets. Collaborations with larger pharmaceutical companies or diagnostic imaging firms could provide access to funding, expertise, and commercialization infrastructure. The biotechnology industry is characterized by frequent partnerships and licensing deals, allowing companies to share risks and rewards. Successful partnerships could help Navidea overcome its financial challenges and accelerate the development and commercialization of its products.
- Exploration of Immunotherapeutic Applications: Beyond diagnostics, Navidea is exploring the use of the Manocept platform for immunotherapeutic applications, targeting macrophages and immune- and inflammation-involved diseases. The global immunotherapeutics market is experiencing rapid growth, driven by advancements in immuno-oncology and autoimmune disease therapies. The market is expected to reach $120 billion by 2028. Expanding into immunotherapeutics could diversify Navidea's revenue streams and position it for long-term growth, provided it can secure necessary funding and navigate the complexities of drug development and regulatory approval.
What Are NAVBQ's Competitive Advantages?
- Proprietary Manocept platform.
- Pipeline of clinical-stage immunodiagnostic agents.
- Intellectual property protection (patents).
- Expertise in targeting the CD206 mannose receptor.
What Does NAVBQ Do?
Navidea Biopharmaceuticals, Inc., founded in 1983 and headquartered in Dublin, Ohio, is a biopharmaceutical company specializing in the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company's core technology revolves around the Manocept platform, which targets the CD206 mannose receptor expressed on activated macrophages. This platform is designed for various diagnostic modalities, including single-photon emission computed tomography (SPECT), positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection. Additionally, Manocept is intended for the delivery of therapeutic compounds targeting macrophages and immune- and inflammation-involved diseases. Navidea's pipeline includes NAV3-31, which has completed Phase IIb clinical trials for rheumatoid arthritis (RA) imaging, focusing on evaluating imaging repeatability, reproducibility, and stability. NAV3-35 is also in Phase IIb clinical trial for RA imaging, NAV3-33 is in Phase III clinical trial for RA, and NAV3-32 is in Phase 2b trial for RA-involved joints. The company is also exploring the use of Tc99m tilmanocept for cardiovascular applications, Kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. Formerly known as Neoprobe Corporation until January 2012, Navidea filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware on October 1, 2025. This action reflects the company's ongoing financial challenges and efforts to restructure its operations and debt.
What Products and Services Does NAVBQ Offer?
- Develops precision immunodiagnostic agents.
- Develops precision immunotherapeutics.
- Focuses on the Manocept platform targeting the CD206 mannose receptor.
- Develops diagnostic modalities including SPECT and PET.
- Develops therapeutic compounds targeting macrophages.
- Targets immune- and inflammation-involved diseases.
- Conducts clinical trials for rheumatoid arthritis imaging.
How Does NAVBQ Make Money?
- Develops and commercializes diagnostic substances.
- Develops therapeutic programs.
- Out-licenses or partners its technology.
- Generates revenue through sales of diagnostic agents (historically).
What Industry Does NAVBQ Operate In?
Navidea Biopharmaceuticals, Inc. operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. Companies like CRXM, GDBYF, GLSHQ, and GNBT are also active in the biotechnology space, focusing on various therapeutic areas and diagnostic technologies. The industry is driven by innovation and the development of novel therapies, but it also faces challenges related to funding, clinical trial success rates, and market access. Navidea's focus on immunodiagnostic agents and immunotherapeutics places it within a niche segment of the broader biotechnology market, but its financial struggles and Chapter 11 filing present significant hurdles.
Who Are NAVBQ's Key Customers?
- Hospitals and imaging centers.
- Research institutions.
- Pharmaceutical companies (potential partners).
- Patients requiring diagnostic imaging.
Insider Activity
The most recent 10 insider filings for Navidea Biopharmaceuticals, Inc. break down as 2 sales and 8 purchases. On net that is roughly 25.3M shares acquired (about $1.1M) — insiders putting money in tends to read as conviction.
Financial Health
Navidea Biopharmaceuticals, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for Navidea Biopharmaceuticals, Inc. stands at 355.3%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.32 means current liabilities exceed short-term assets, a liquidity point worth watching.
Navidea Biopharmaceuticals, Inc. (NAVBQ) Valuation Context
Relative to its peer group, NAVBQ's quantitative score of 43/100 is below the peer average of 76/100.
Company Profile
Navidea Biopharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Dublin, US. The company is led by CEO Craig A. Dais. NAVBQ has traded publicly since 1992.
NAVBQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that those closest to the business believe in its potential.
- Community sentiment has shifted positively, with discussions around upcoming clinical trial results generating excitement among investors.
- The focus on innovative therapies for autoimmune diseases aligns with current healthcare trends, attracting interest from long-term investors.
- Strategic partnerships in the biopharmaceutical space have bolstered market perception, enhancing credibility and visibility.
Bear Case
- Concerns about funding and cash flow have surfaced, raising doubts about the company's ability to sustain operations in the near term.
- Negative sentiment from some community members reflects skepticism about the efficacy of ongoing clinical trials, leading to caution among potential investors.
- Market volatility in the biotech sector could impact Navidea's stock performance, as broader trends often overshadow individual company developments.
- Recent regulatory challenges have created uncertainty, making some investors wary of the company's ability to navigate compliance effectively.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
NAVBQ Latest News
No recent news available for NAVBQ.
NAVBQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NAVBQ.
Price Targets
Wall Street price target analysis for NAVBQ.
NAVBQ MoonshotScore
What does this score mean?
The MoonshotScore rates NAVBQ 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Craig A. Dais
CEO
Craig A. Dais serves as the CEO of Navidea Biopharmaceuticals, Inc. His background includes experience in managing teams and overseeing operations within the biopharmaceutical sector. With a focus on strategic leadership, Dais is responsible for guiding Navidea through its current challenges and restructuring efforts. His expertise is crucial in navigating the company's pipeline development and commercialization strategies.
Track Record: Under Craig A. Dais's leadership, Navidea has focused on advancing its clinical trials and exploring strategic alternatives amidst financial constraints. His tenure has been marked by efforts to maintain operations and pursue potential partnerships, despite the company's Chapter 11 filing. Key decisions have involved prioritizing pipeline development and seeking avenues for financial restructuring.
NAVBQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Navidea Biopharmaceuticals, Inc. does not meet the minimum financial standards or reporting requirements for the higher tiers like OTCQX or OTCQB. Companies in this tier may be distressed, bankrupt, or have limited information available to investors. Trading on the OTC Other tier carries significant risks compared to exchanges like the NYSE or NASDAQ, which have stricter listing requirements and greater regulatory oversight.
- OTC Tier: OTC Other
- Limited information and disclosure due to OTC Other tier status.
- High risk of delisting or trading suspension.
- Potential for price manipulation and fraud.
- Significant financial distress and Chapter 11 bankruptcy.
- Limited liquidity and wide bid-ask spreads.
- Verify the company's current legal status and Chapter 11 proceedings.
- Obtain and review any available financial statements and disclosures.
- Assess the company's ability to continue as a going concern.
- Evaluate the potential for restructuring and recovery.
- Understand the risks associated with OTC trading.
- Consult with a financial advisor.
- Check for any regulatory actions or investigations.
- History as a publicly traded company (formerly Neoprobe Corporation).
- Development of the Manocept platform and pipeline of immunodiagnostic agents.
- Prior clinical trial activity and regulatory filings.
- Presence of a CEO and management team.
- Headquarters in Dublin, Ohio.
Common Questions About NAVBQ (Healthcare)
What does the AI Score mean for NAVBQ?
NAVBQ holds an AI Score of 43/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing precision immunodiagnostic agents and immunotherapeutics. The company filed for Chapter 11 …
What does Navidea Biopharmaceuticals, Inc. do?
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing precision immunodiagnostic agents and immunotherapeutics. Its core technology is the Manocept platform, which targets the CD206 mannose receptor on activated macrophages. This platform is designed for diagnostic modalities like SPECT and PET, as well as for delivering therapeutic compounds to treat immune- and inflammation-involved diseases.
What do analysts say about NAVBQ stock?
Given Navidea Biopharmaceuticals, Inc.'s Chapter 11 reorganization filing and OTC Other tier status, formal analyst coverage is likely limited or non-existent. Key valuation metrics such as P/E ratio (-0.00) and market capitalization ($0.00B) are not meaningful in the current context.
What are the main risks for NAVBQ?
The primary risk for Navidea Biopharmaceuticals, Inc. is its Chapter 11 reorganization, which introduces significant uncertainty about its future viability. Other risks include limited financial resources, dependence on clinical trial success, competition from larger biotechnology companies, regulatory hurdles, and the illiquidity and potential for manipulation associated with OTC trading.
What are the key factors to evaluate for NAVBQ?
Navidea Biopharmaceuticals, Inc. (NAVBQ) holds an AI score of 43/100 (low). faces significant challenges given its Chapter 11 reorganization filing in October 2025. Not financial advice.
How frequently does NAVBQ data refresh on this page?
NAVBQ's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven NAVBQ's recent stock price performance?
Navidea Biopharmaceuticals, Inc. (NAVBQ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary Manocept platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NAVBQ overvalued or undervalued right now?
Navidea Biopharmaceuticals, Inc. (NAVBQ) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research NAVBQ before investing?
Before investing in Navidea Biopharmaceuticals, Inc. (NAVBQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available sources and may be limited due to the company's OTC status and Chapter 11 filing.
- Financial data may not be current or fully reliable.